In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Denali options Blaze's BBB-crossing therapeutics

Executive Summary

Denali Therapeutics Inc. is collaborating with Blaze Bioscience Inc. on the discovery of therapeutics capable of crossing the blood-brain-barrier (BBB), a protective mechanism that prevents harmful chemicals in the blood from passing into the brain.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register